Chargement en cours...
Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status
AIMS: Rabeprazole is known to be a substrate of CYP2C19. Our objective was to evaluate the possible effect of an inhibitor of CYP2C19, fluvoxamine, and compare the inhibitory effect of fluvoxamine on the metabolism of rabeprazole between CYP2C19 genotypes. METHODS: A two-way randomized double-blind,...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Blackwell Science Inc
2006
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1885025/ https://ncbi.nlm.nih.gov/pubmed/16487224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2005.02556.x |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|